MedTrace Logo

Treatable Traits in Interstitial Lung Disease

NCT06626438 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-10-07

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a personalised treatment model of care "treatable traits" can improve quality of life and disease progression in patients with interstitial lung disease.

The main question it aims to answer is, will providing a treatable traits model of care improve health-related quality of life (HRQoL) (primary outcome), symptoms, anxiety, physical activity, and body composition (secondary outcomes).

Researchers will compare the treatable traits model to standard of care.

Participants in both arms will complete surveys, a Dual-Energy X-Ray Absorptiometry (DEXA) and whole-body composition scan, lung function and blood tests. Those in the intervention (TT) arm will be seen in a multidisciplinary clinic where they are seen by an ILD doctor, physiotherapist, psychologist, and dietitian.

Conditions

  • Interstitial Lung Diseases (ILD)

Interventions

OTHER

Treatable traits model of care

Embedded multidisciplinary clinic with treatable traits model of care.

Sponsors & Collaborators

  • Fiona Stanley Hospital

    collaborator OTHER

  • Sir Charles Gairdner Hospital

    collaborator OTHER

  • The University of Western Australia

    lead OTHER

Principal Investigators

  • Yuben Moodley, MBSS, FRACP, MD, PHD · The University of Western Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-03
Primary Completion
2026-12-31
Completion
2027-07-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06626438 on ClinicalTrials.gov